CellaVision AB
C26
Company Profile
Business description
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers or software.
Contact
Mobilvagen 12
Lund22362
SWET: +46 464601600
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
250
Stocks News & Analysis
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
stocks
Magellan Financial Group: A dilutive acquisition of Barrenjoey
Our view of the proposed merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,297.20 | 103.50 | -1.10% |
| CAC 40 | 8,104.51 | 289.81 | -3.45% |
| DAX 40 | 23,649.41 | 988.59 | -4.01% |
| Dow JONES (US) | 47,725.35 | 1,179.43 | -2.41% |
| FTSE 100 | 10,435.14 | 344.97 | -3.20% |
| HKSE | 25,768.08 | 291.77 | -1.12% |
| NASDAQ | 22,174.44 | 574.42 | -2.53% |
| Nikkei 225 | 56,279.05 | 1,778.19 | -3.06% |
| NZX 50 Index | 13,620.21 | 36.44 | -0.27% |
| S&P 500 | 6,723.33 | 158.29 | -2.30% |
| S&P/ASX 200 | 9,077.30 | 90.80 | -0.99% |
| SSE Composite Index | 4,122.68 | 59.92 | -1.43% |